Is biparametric MRI a feasible option for detecting clinically significant prostate cancer?: A systematic review and meta-analysis.
[BACKGROUND] Multiparametric MRI (Mp-MRI) is a key tool to screen for Prostate Cancer (Pca) and Clinically Significant Prostate Cancer (CsPca).
- 연구 설계 systematic review
APA
Garcia-Becerra CA, Arias-Gallardo MI, et al. (2025). Is biparametric MRI a feasible option for detecting clinically significant prostate cancer?: A systematic review and meta-analysis.. Urologic oncology, 43(6), 396.e9-396.e17. https://doi.org/10.1016/j.urolonc.2024.12.262
MLA
Garcia-Becerra CA, et al.. "Is biparametric MRI a feasible option for detecting clinically significant prostate cancer?: A systematic review and meta-analysis.." Urologic oncology, vol. 43, no. 6, 2025, pp. 396.e9-396.e17.
PMID
39753482
Abstract
[BACKGROUND] Multiparametric MRI (Mp-MRI) is a key tool to screen for Prostate Cancer (Pca) and Clinically Significant Prostate Cancer (CsPca). It primarily includes T2-Weighted imaging (T2w), diffusion-weighted imaging (DWI), and Dynamic Contrast-Enhanced imaging (DCE). Despite its improvements in CsPca screening, concerns about the cost-effectiveness of DCE persist due to its associated side effects, increased cost, longer acquisition time, and limitations in patients with poor kidney function. Recent studies have explored Biparametric MRI (Bp-MRI) as an alternative that excludes DCE.
[OBJECTIVES] The main objective of this study is to compile and evaluate updated results of Bp-MRI as a diagnostic alternative to detect CsPca.
[METHODS] A systematic review was conducted using PubMed, Central Cochrane, and ClinicalTrialls.gov registry. Inclusion criteria was focused on observational and experimental studies that assessed a direct comparison of Bp-MRI and Mp-MRI for CsPca detection. The primary outcomes included were necessary to create a contingency 2×2 table and CsPca prevalence from each study. The secondary outcomes included were demographic data and imaging protocol features. The statistical analysis used a Bivariate Random-Effect model to estimate the pooled sensitivity, specificity, and area under the curve (AUC). An univariate random-effect model was conducted to estimate the positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies -2 tool.
[RESULTS] From 534 articles initially identified, 19 studies met the inclusion criteria with a total of 5075 patients. The pooled sensitivity estimated was 0.89, pooled specificity was 0.73, and AUC was 0.90; these results showed a slight increase compared to previous studies.
[CONCLUSION] The results obtained showed that Bp-MRI is a feasible alternative to detect CsPca, which demonstrates high diagnostic accuracy and avoids the drawbacks associated with DCE.
[REGISTRY] This is a sub-analysis of the protocol registered at PROSPERO (CRD42024552125).
[OBJECTIVES] The main objective of this study is to compile and evaluate updated results of Bp-MRI as a diagnostic alternative to detect CsPca.
[METHODS] A systematic review was conducted using PubMed, Central Cochrane, and ClinicalTrialls.gov registry. Inclusion criteria was focused on observational and experimental studies that assessed a direct comparison of Bp-MRI and Mp-MRI for CsPca detection. The primary outcomes included were necessary to create a contingency 2×2 table and CsPca prevalence from each study. The secondary outcomes included were demographic data and imaging protocol features. The statistical analysis used a Bivariate Random-Effect model to estimate the pooled sensitivity, specificity, and area under the curve (AUC). An univariate random-effect model was conducted to estimate the positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies -2 tool.
[RESULTS] From 534 articles initially identified, 19 studies met the inclusion criteria with a total of 5075 patients. The pooled sensitivity estimated was 0.89, pooled specificity was 0.73, and AUC was 0.90; these results showed a slight increase compared to previous studies.
[CONCLUSION] The results obtained showed that Bp-MRI is a feasible alternative to detect CsPca, which demonstrates high diagnostic accuracy and avoids the drawbacks associated with DCE.
[REGISTRY] This is a sub-analysis of the protocol registered at PROSPERO (CRD42024552125).
MeSH Terms
Humans; Male; Magnetic Resonance Imaging; Multiparametric Magnetic Resonance Imaging; Prostatic Neoplasms
같은 제1저자의 인용 많은 논문 (3)
- Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials.
- Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer-a bivariate meta-analysis of prospective studies.
- Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis.